Anti-inflammatory biotech Aldeyra teams up with Janssen

Aldeyra and Janssen will develop novel drugs that sequester pro-inflammatory aldehyde mediators. (Image: Gerd Altmann)

Aldeyra Therapeutics and Janssen inked a pact to develop new drugs for autoimmune and other inflammatory diseases. For a limited time, Janssen has the option to license any compounds developed under the deal.

Aldeyra is targeting aldehydes—which can activate certain pro-inflammatory factors—to fight inflammation. Its lead compound, reproxalap, is a small-molecule trap designed to lower free aldehyde levels that’s in the clinic for dry eye disease, allergic conjunctivitis, uveitis and Sjögren-Larsson syndrome.

Last June, reproxalap missed its primary endpoint in a phase 2b trial, failing to sufficiently improve eye itching over placebo in patients with allergic conjunctivitis. And in September, the Lexington, Massachusetts-based biotech turned up a mixed bag of results for a phase 2a trial in dry eye disease.

FierceBiotech Executive Breakfast

Getting Real: The Changing Tide on Real-World Evidence in Drug Development

Join FierceBiotech and a panel of industry experts for an executive breakfast at BIO. We will discuss the impacts of real-world evidence on drug development and address the important questions that companies are facing including where to find the right talent & technology and how to deploy it internally or with partners. Join us in Philadelphia on June 5th for this important discussion.

But Aldeyra has been keeping positive, saying in June it was already looking beyond its upcoming end of phase 2 meeting with the FDA to a late-stage study.

The Janssen collab comes at a good time—the pair will work on novel drugs that sequester pro-inflammatory aldehyde mediators, according to a statement. Specifically, the agreement is geared toward advancing Aldeyra’s other aldehyde trap candidates.

"As we are committed to the development of novel therapeutic product candidates for autoimmune and other diseases characterized by systemic inflammation, we are pleased to partner with Janssen, a world leader in the discovery and development of therapeutics for inflammatory diseases," said Aldeyra CEO Todd Brady.

Suggested Articles

Yale researchers discovered that AstraZeneca’s anti-VEGF cancer drug cediranib may boost the effectiveness of PARP inhibitors.

The FBI has launched its own probe into some of the world’s largest medtech companies, stemming from a Brazilian corruption case, Reuters reports.

AbbVie became yet another biopharma learning that aggressive brain cancer glioblastoma is one of the toughest cancers out there.